Cover Image
市場調查報告書

MediPoint:類風濕性關節炎 (RA) 檢驗 - 全球市場的分析與預測

MediPoint: Rheumatoid Arthritis Testing - Global Analysis and Market Forecasts

出版商 GlobalData 商品編碼 370546
出版日期 內容資訊 英文 149 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:類風濕性關節炎 (RA) 檢驗 - 全球市場的分析與預測 MediPoint: Rheumatoid Arthritis Testing - Global Analysis and Market Forecasts
出版日期: 2016年06月11日 內容資訊: 英文 149 Pages
簡介

本報告提供全球類風濕性關節炎 (RA) 檢驗市場相關調查分析,市場進入,未滿足需求,競爭評估,主要企業,市場預測等系統性資訊。

第1章 目錄

第2章 簡介

第3章 市場進入

  • RA檢驗概要
  • 償付趨勢
  • M&A,主要的聯盟

第4章 未滿足需求

  • 早期診斷
  • 血清反應陰性和靈敏度
  • RA診斷用的新生物標記

第5章 競爭評估

  • 企業佔有率分析
  • Abbott Diagnostics
  • Beckman Coulter
  • Bio-Rad Laboratories
  • Euro-Diagnostica
  • Inova Diagnostics
  • Quest Diagnostics
  • F. Hoffmann-La Roche
  • Siemens Healthcare
  • SQI Diagnostics
  • Thermo Fisher Scientific
  • 其他

第6章 市場預測

  • 檢驗趨勢
  • 市場動態
  • 市場預測:各市場區隔
  • 市場預測:各地區

第7章 附錄

目錄
Product Code: GDME0230MAR

Rheumatoid Arthritis (RA) is the commonest autoimmune disease in humans. The disease is prevalent in all ethnic groups, affecting approximately 1.0% of the world population. Presently there is a huge presence of unmet patient needs for both the treatment and diagnosis.

Focus for the treatment paradigm has now shifted towards the early detection and diagnosis of the disease, which will allow physicians to begin aggressive treatment of the condition, minimizing the associated complications and tissue damage.

Global sales of $347m in 2016 and estimated growth rate of 2% during the forecast period; the emerging markets: Brazil, Canada, China and Mexico are expected to show the fastest growth.

Key market drivers -

  • Increasing prevalence of autoimmune diseases globally including RA
  • Emerging biomarkers and advancement in technology for the early diagnosis of RA
  • Increasing adoption of anti-cyclic citrullinated peptide (anti-CCP) antibody test
  • Rising demand for lab automation

Key market barriers -

  • Limited sensitivity of existing RA diagnostic tests
  • Healthcare cost-cutting and reduced reimbursement in major markets

Highlights

Key Questions Answered

  • What is the current and future RA testing market outlook in the developed and emerging markets? What trends are affecting the global market?
  • What is the competitive landscape and who are major players in the RA testing space?
  • What are the key, high growth markets that IVD manufacturers should expand into? Which market segments are growing the fastest?
  • What are the unmet needs with the RA tests currently on the market? How will emerging technologies such as POC assays fulfil these unmet needs?
  • What are the key products and pipelines in the RA testing market?
  • What are the challenges and barriers that have hindered widespread adoption of RA tests in different regions?

Scope

  • Competitive assessment: Currently marketed RA diagnostic products and evolving competitive landscape
  • In-depth analysis of unmet needs and adoption trends of different RA diagnostic tests
  • Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
  • Pipeline analysis: Emerging products and technologies.
  • Annualized total RA testing market revenue by segment and market outlooks by country from 2013-2022.
  • Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
  • Develop business strategies by understanding the trends shaping and driving the global market
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Track device sales in the global market from 2012-2021
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Market Access

  • 3.1. Rheumatoid Arthritis Testing Overview
  • 3.2. Reimbursement Trends
    • 3.2.1. North America
    • 3.2.2. Europe
    • 3.2.3. Asia-Pacific
    • 3.2.4. South America
  • 3.3. Mergers, Acquisitions, and Key Partnerships

4. Unmet Needs

  • 4.1. Earlier Diagnosis
  • 4.2. Seronegativity and Sensitivity
    • 4.2.1. Rheumatoid Factor
    • 4.2.2. Anti-Cyclic Citrullinated Peptide Antibody
    • 4.2.3. 14-3-3η
  • 4.3. Novel Biomarkers for Rheumatoid Arthritis Diagnosis

5. Competitive Assessment

  • 5.1. Company Share Analysis
    • 5.1.1. Global
  • 5.2. Abbott Diagnostics
    • 5.2.1. Overview
    • 5.2.2. Marketed Products Assessment
    • 5.2.3. SWOT Analysis
  • 5.3. Beckman Coulter
    • 5.3.1. Overview
    • 5.3.2. Marketed Products Assessment
    • 5.3.3. Pipeline Products Assessment
    • 5.3.4. SWOT Analysis
  • 5.4. Bio-Rad Laboratories
    • 5.4.1. Overview
    • 5.4.2. Marketed Products Assessment
    • 5.4.3. SWOT Analysis
  • 5.5. Euro-Diagnostica
    • 5.5.1. Overview
    • 5.5.2. Marketed Products Assessment
    • 5.5.3. SWOT Analysis
  • 5.6. Inova Diagnostics
    • 5.6.1. Overview
    • 5.6.2. Marketed Products Assessment
    • 5.6.3. SWOT Analysis
  • 5.7. Quest Diagnostics
    • 5.7.1. Overview
    • 5.7.2. Marketed Products Assessment
    • 5.7.3. SWOT Analysis <4/ul>
    • 5.8. F. Hoffmann-La Roche
      • 5.8.1. Overview
      • 5.8.2. Marketed Products Assessment
      • 5.8.3. SWOT Analysis
    • 5.9. Siemens Healthcare
      • 5.9.1. Overview
      • 5.9.2. Marketed Products Assessment
      • 5.9.3. Pipeline Products Assessment
      • 5.9.4. SWOT Analysis
    • 5.10. SQI Diagnostics
      • 5.10.1. Overview
      • 5.10.2. Marked Products Assessment
      • 5.10.3. SWOT Analysis
    • 5.11. Thermo Fisher Scientific
      • 5.11.1. Overview
      • 5.11.2. Marketed Products Assessment
      • 5.11.3. Pipeline Products Assessment
      • 5.11.4. SWOT Analysis
    • 5.12. Other Companies

6. Market Outlook

  • 6.1. Test Trends
    • 6.1.1. Rheumatoid Factor Testing
    • 6.1.2. Anti-Cyclic Citrullinated Peptide Antibody Testing
    • 6.1.3. C-Reactive Protein Testing
  • 6.2. Market Dynamics
    • 6.2.1. Driver: Increasing Anti-CCP Antibody Testing
    • 6.2.2. Driver: Innovative Tests for Rheumatoid Arthritis
    • 6.2.3. Driver: Rising Demand for Lab Automation
    • 6.2.4. Driver: Rising Prevalence of Rheumatoid Arthritis
    • 6.2.5. Barrier: Limited Sensitivity of Existing Tests
    • 6.2.6. Barrier: Healthcare Cost-Cutting
    • 6.2.7. Barrier: Medical Device Excise Tax
  • 6.3. Market Outlooks by Segment
    • 6.3.1. Global Overview
    • 6.3.2. Rheumatoid Factor Tests
    • 6.3.3. Anti-Cyclic Citrullinated Peptide Antibody Tests
    • 6.3.4. C-Reactive Protein Tests
  • 6.4. Market Outlooks by Geography
    • 6.4.1. Global Overview
    • 6.4.2. US
    • 6.4.3. France
    • 6.4.4. Germany
    • 6.4.5. Italy
    • 6.4.6. Spain
    • 6.4.7. UK
    • 6.4.8. Japan
    • 6.4.9. Australia
    • 6.4.10. Brazil
    • 6.4.11. Canada
    • 6.4.12. China
    • 6.4.13. India
    • 6.4.14. Mexico
    • 6.4.15. Russia
    • 6.4.16. South Korea

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Report Methodology
    • 7.3.1. Overview
    • 7.3.2. Coverage
    • 7.3.3. Secondary Research
    • 7.3.4. Forecasting Methodology
    • 7.3.5. Primary Research - Key Opinion Leader Interviews
    • 7.3.6. Primary Research - Physician and Industry Interviews
    • 7.3.7. Expert Panel Validation
  • 7.4. About the Team
    • 7.4.1. Analysts
    • 7.4.2. David Brady, Director of Operations - Market Research
    • 7.4.3. Tyler Fletcher, Global Head of Medical Devices
  • 7.5. About MediPoint
  • 7.6. About GlobalData
  • 7.7. Disclaimer

List of Tables

  • Table 1: Rheumatoid Arthritis Classification Criteria
  • Table 2: Medicare National Average of Clinical Laboratory Services Reimbursement for Rheumatoid Arthritis Testing, 2014-2015
  • Table 3: Mergers, Acquisitions, and Key Partnerships, 2014-2016
  • Table 4: Company Profile - Abbott Diagnostics
  • Table 5: Abbott Diagnostics' RA Testing Portfolio Assessment, 2016
  • Table 6: SWOT Analysis - Abbott Diagnostics
  • Table 7: Company Profile - Beckman Coulter
  • Table 8: Beckman Coulter's RA Testing Portfolio Assessment, 2016
  • Table 9: Beckman Coulter's RA Testing Pipeline, 2016
  • Table 10: SWOT Analysis - Beckman Coulter
  • Table 11: Company Profile - Bio-Rad Laboratories
  • Table 12: Bio-Rad Laboratories' RA Testing Portfolio Assessment, 2016
  • Table 13: SWOT Analysis - Bio-Rad Laboratories
  • Table 14: Company Profile - Euro-Diagnostica
  • Table 15: Euro-Diagnostica's RA Testing Portfolio Assessment, 2016
  • Table 16: SWOT Analysis - Euro-Diagnostica
  • Table 17: Company Profile - Inova Diagnostics
  • Table 18: Inova Diagnostics' RA Testing Portfolio Assessment, 2016
  • Table 19: SWOT Analysis - Inova Diagnostics
  • Table 20: Company Profile - Quest Diagnostics
  • Table 21: Quest Diagnostics' RA Testing Portfolio Assessment, 2016
  • Table 22: SWOT Analysis - Quest Diagnostics
  • Table 23: Company Profile - F. Hoffmann-La Roche
  • Table 24: F. Hoffmann-La Roche's RA Testing Portfolio Assessment, 2016
  • Table 25: SWOT Analysis - F. Hoffmann-La Roche
  • Table 26: Company Profile - Siemens Healthcare
  • Table 27: Siemens Healthcare's RA Testing Portfolio Assessment, 2016
  • Table 28: Siemens Healthcare's RA Testing Pipeline, 2016
  • Table 29: SWOT Analysis - Siemens Healthcare
  • Table 30: Company Profile - SQI Diagnostics
  • Table 31: SQI Diagnostics' RA Testing Portfolio Assessment, 2016
  • Table 32: SWOT Analysis - SQI Diagnostics
  • Table 33: Company Profile - Thermo Fisher Scientific
  • Table 34: Thermo Fisher Scientific's RA Testing Portfolio Assessment, 2016
  • Table 35: Thermo Fisher Scientific's RA Testing Pipeline, 2016
  • Table 36: SWOT Analysis - Thermo Fisher Scientific
  • Table 37: Other Companies Involved in the Rheumatoid Arthritis Testing Market, 2016
  • Table 38: Global RF Test Volume Forecast (thousands) by Country, 2013-2022
  • Table 39: Global Anti-CCP Antibody Test Volume Forecast (thousands) by Country, 2013-2022
  • Table 40: Global CRP Test Volume Forecast (thousands) by Country, 2013-2022
  • Table 41: Global Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 42: RF Marker Tests Sales Forecast ($m) by Region, 2013-2022
  • Table 43: Anti-CCP Antibody Marker Test Sales Forecast ($m) by Region, 2013-2022
  • Table 44: CRP Marker Test Sales Forecast ($m) by Region, 2013-2022
  • Table 45: Global Rheumatoid Arthritis Testing Sales Forecast ($m) by Country, 2013-2022
  • Table 46: US Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 47: France Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 48: Germany Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 49: Italy Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 50: Spain Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 51: UK Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 52: Japan Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 53: Australia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 54: Brazil Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 55: Canada Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 56: China Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 57: India Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 58: Mexico Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 59: Russia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 60: South Korea Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Table 61: Rheumatoid Arthritis Testing - Primary Call Count by Country

List of Figures

  • Figure 1: Global RA Testing Market, By Company Share, 2015
  • Figure 2: Global RF Test Volume Forecast (thousands) by Country, 2013-2022
  • Figure 3: Global RF Test Volume Share Forecast (%) by Country, 2015 and 2022
  • Figure 4: Global Anti-CCP Antibody Test Volume Forecast (thousands) by Country, 2013-2022
  • Figure 5: Global Anti-CCP Antibody Test Volume Share Forecast (%) by Country, 2015 and 2022
  • Figure 6: Global CRP Test Volume Forecast (thousands) by Country, 2013-2022
  • Figure 7: Global CRP Test Volume Share Forecast (%) by Country, 2015 and 2022
  • Figure 8: Global Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 9: Global Rheumatoid Arthritis Analyzer Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 10: Global Rheumatoid Arthritis Manual Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 11: Global Rheumatoid Arthritis Testing Market Potential by Test, 2022
  • Figure 12: RF Marker Tests Sales Forecast ($m) by Region, 2013-2022
  • Figure 13: Anti-CCP Antibody Marker Test Sales Forecast ($m) by Region, 2013-2022
  • Figure 14: CRP Marker Test Sales Forecast ($m) by Region, 2013-2022
  • Figure 15: Global Rheumatoid Arthritis Testing Sales Forecast ($m), 2013-2022
  • Figure 16: Global Rheumatoid Arthritis Testing Market Share Forecast (%) by Country, 2015 and 2022
  • Figure 17: Global Rheumatoid Arthritis Testing Market Potential by Country, 2022
  • Figure 18: US Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 19: US Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 20: France Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 21: France Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 22: Germany Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 23: Germany Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 24: Italy Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 25: Italy Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 26: Spain Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 27: Spain Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 28: UK Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 29: UK Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 30: Japan Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 31: Japan Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 32: Australia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 33: Australia Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 34: Brazil Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 35: Brazil Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 36: Canada Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 37: Canada Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 38: China Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 39: China Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 40: India Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 41: India Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 42: Mexico Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 43: Mexico Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 44: Russia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 45: Russia Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 46: South Korea Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
  • Figure 47: South Korea Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
  • Figure 48: Rheumatoid Arthritis Testing - Primary Call Count by Country (N=75)
Back to Top